Entrada Therapeutics Inc (TRDA)
16.45
+0.68
(+4.31%)
USD |
NASDAQ |
Sep 27, 16:00
16.47
+0.02
(+0.12%)
After-Hours: 20:00
Entrada Therapeutics Revenue (Quarterly): 94.69M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 94.69M |
March 31, 2024 | 59.12M |
December 31, 2023 | 41.85M |
Date | Value |
---|---|
September 30, 2023 | 43.74M |
June 30, 2023 | 18.17M |
March 31, 2023 | 25.26M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
18.17M
Minimum
Jun 2023
94.69M
Maximum
Jun 2024
47.14M
Average
42.79M
Median
Revenue (Quarterly) Benchmarks
Fulcrum Therapeutics Inc | 80.00M |
Pfizer Inc | 13.28B |
Sarepta Therapeutics Inc | 362.93M |
Catalyst Pharmaceuticals Inc | 122.71M |
Insmed Inc | 90.34M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 55.03M |
Total Expenses (Quarterly) | 41.27M |
EPS Diluted (Quarterly) | 1.55 |
Enterprise Value | 142.19M |
Profit Margin (Quarterly) | 58.11% |
Earnings Yield | 17.99% |
Operating Earnings Yield | 16.41% |
Normalized Earnings Yield | 17.99 |